Sales and Marketing

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage { grid-column-gap: 15px;grid-row-gap: 15px; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(4n + 1) { grid-area:  auto / auto / span 3 / span 7; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(4n + 2) { grid-area:  auto / auto / span 3 / span 5; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(4n + 3) { grid-area:  auto / auto / span 3 / span 5; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(4n + 4) { grid-area:  auto / auto / span 3 / span 7; } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="a552fc9653458e0d202e306ac0a1e0e3"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="40b05292f70a70284b1c1668151484af"] { background: rgba( 250, 246, 246, 1 );padding: 0px;border: 1px solid rgba( 218, 218, 218, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="e4b67e6ba862390ef804aaac3ef418a9"] { background: rgba( 250, 246, 246, 1 );padding: 15px 20px 10px 20px;margin-top: 0px;border: 0px solid rgba( 0, 0, 0, 1 ); } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__link { background-color: rgba( 207, 46, 46, 1 );font-size: 12px;text-transform: capitalize; } .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__icon { font-family: dashicons; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="d2e2b11f87f20192f81acf521a2702ac"] .tb-button__link { background-color: rgba( 155, 81, 224, 1 );font-size: 12px;text-transform: capitalize; } .tb-button[data-toolset-blocks-button="d2e2b11f87f20192f81acf521a2702ac"] .tb-button__icon { font-family: dashicons; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="f5edf74ba0d6c65cc57b11e8dbedbdab"] { padding-bottom: 10px; }  .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} .wp-block-image.tb-image[data-toolset-blocks-image="7a063356861243c5612fe8fa5d8352bd"] { max-width: 100%; } .wp-block-image.tb-image[data-toolset-blocks-image="7a063356861243c5612fe8fa5d8352bd"] img { background-color: rgba( 250, 246, 246, 1 );border: 0px solid rgba( 0, 0, 0, 1 ); } .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(3n + 1) { grid-area:  auto / auto / span 3 / span 12; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(3n + 2) { grid-area:  auto / auto / span 4 / span 6; } .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(3n + 3) { grid-area:  auto / auto / span 4 / span 6; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="5fee85629ec82896601e49a72eb00903"] .wpv-collage > div:nth-child(1n + 1) { grid-area:  auto / auto / span 6 / span 12; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} } 

Mobile telehealth to create ‘doctor in your pocket’ convenience

October 17, 2014 Medical Communications, Sales and Marketing frost and sullivan, health, telehealth, videoconferencing, wearables

The telehealth industry is on the verge of a dramatic growth surge that is significantly disrupting the healthcare sector in …

News

Novartis cancer drug beating path to NHS

October 17, 2014 Sales and Marketing GIST, Glivec, NHS, NICE, imatinib, uturn

NICE has issued final draft guidance recommending Novartis’s Glivec for up to three years in people who have had a …

News

Four promotions at Red Door Communications

October 17, 2014 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kate Aldous, Katy Pogson, Matt Lowe, Red Door Communications, Sarah Aldridge

Red Door Communications (RDC) has promoted Matt Lowe and Katy Pogson to its board of directors, and Kate Aldous and …

Appointment

New cancer drugs escalate Roche earnings

October 16, 2014 Research and Development, Sales and Marketing Cancer, Herceptin (trastuzumab), Kadcyla, Perjeta, Q3, Roche, ado-trastuzumab emtansine, pertuzumab

Roche’s sales saw solid growth in the first nine months of the year, increased by the firm’s new cancer medicines. …

News

AstraZeneca deepens Cambridge ties

October 16, 2014 Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, CRUK, Cambridge, MRC, MedImmune

AstraZeneca along with its biologics R&D arm MedImmune are to enter into four new collaborations with the University of Cambridge. …

News

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014 Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News

NICE not recommending Dendreon cancer vaccine

October 16, 2014 Sales and Marketing Dendreon, NHS, NICE, Provenge, sipuleucel-T, therapeutic cancer vaccine

NICE has issued preliminary draft guidance not recommending Dendreon’s therapeutic cancer vaccine Provenge for prostate cancer in people whose disease …

News

Novo Nordisk hires human resources VP

October 16, 2014 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jackie Scanlan, Novo Nordisk

Novo Nordisk has appointed Jackie Scanlan to join its executive team as the corporate vice president of its human resources …

Appointment

AbbVie reconsiders Shire deal over tax laws

October 15, 2014 Medical Communications, Sales and Marketing AbbVie, Abbott, Obama, Shire, US, mergers, tax

AbbVie will reconsider its planned $54.6 billion takeover of Shire in light of new US proposals designed to curb companies …

News

BT and Exostar partner on research software

October 15, 2014 Medical Communications, Research and Development, Sales and Marketing BT, cloud, exostar, iam, life sciences, software, workbench

Cloud computing company Exostar has become a partner of BT for Life Sciences, allowing its Identity and Access Management (IAM) …

News

Telescope implant for macular degeneration approved

October 15, 2014 Medical Communications, Sales and Marketing FDA, VisionCare Ophthalmic Technologies, macular degeneration, telescope implant

Medical device development firm VisionCare Ophthalmic Technologies has had its implantable miniature telescope for age-related macular degeneration disease approved by …

News

FDA approves Eisai’s chemo side-effects drug

October 15, 2014 Research and Development, Sales and Marketing Eisai, FDA, Helsinn, akynzeo, chemotherapy, cinv

Eisai and Helsinn Healthcare’s Akynzeo (netupitant/palonosetron) has received FDA approval for the treatment of chemotherapy-induced nausea and vomiting (CINV). CINV …

News

Scottish Lifesciences Association welcomes chair

October 15, 2014 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ken Sutherland, Scottish Lifesciences Association

The Scottish Lifesciences Association has named Dr Ken Sutherland as its new chair. Sutherland joins from Toshiba Medical Visualisation Systems …

Appointment

BMS, Pharmacyclics and Janssen collaborate on cancer

October 14, 2014 Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo

Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …

News